Tapas & TechTalks

An event for cell and gene therapy leaders!

Process development for cell and gene therapy

Are you looking to better understand the challenges in developing robust processes for cell and gene therapy manufacturing? Do you have in-house process development (PD) capabilities? Are you responsible for key outsourcing decisions, problem solving, and finding new solutions to reach your next milestone quickly? Join us to hear from industry experts in an engaging panel discussion with peer-to-peer insights.

Topics include:

Upstream PD for stem cell manufacturing

Cell expansion and scale-up
Differentiation of pluripotent stem cells

Downstream PD for viral vector manufacturing

Nucleic acid digestion
Clarification and ultrafiltration/diafiltration (UF/DF)
Sterile filtration
25 L case study

This event is part one of the series “Cell & Gene Therapy process development”, consisting of three episodes:

Cell and gene therapy – part 1/3 – Process development
Cell and gene therapy – part 2/3 – Platform development
Cell and gene therapy - part 3/3 - Process validation

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptates natus esse, deserunt necessitatibus numquam amet rerum dicta in, iste sequi cupiditate distinctio voluptate et veritatis.

— quote source

First name:

Last name:

Email address:

Company name:

Country:

Phone Number:

By clicking any of these options, you are agreeing to receive marketing emails, newsletters and other promotional communications from Cytiva from time to time. You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our Privacy policy.

Form Program ID:

Panel 2 header

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Repellendus aliquid tempore natus voluptates repudiandae, eos dolorem libero inventore, quod incidunt, asperiores. Reiciendis itaque enim pariatur, blanditiis minima autem quo a nulla, obcaecati quis, excepturi atque ab rerum! Sequi molestias vel eum, hic, perspiciatis eius suscipit reprehenderit molestiae vitae similique.

${panel2ButtonCTA}

Panel 3 header

${panel3ButtonCTA}

Panel 4 header

Panel 4 header 2

Panel 5 header

Panel 5 header 2

Panel 5 header 3

Gary M. Pigeau, PhD

Director, CATCT

Bio

Gary Pigeau received his PhD in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined Cytiva and the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in 2016. He serves as Director of the collaborative facility in Toronto, Ontario with focus on biology support for New Product Introductions, internal technology development projects, and contract process development services in cell and gene therapy.

Stephie Leung

Development Associate, Cytiva

Bio

Stephie is part of the Cytiva Fast Trak Centre for Advanced Therapeutic Cell Technologies (CATCT), in collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto since January 2017. She works primarily on lentiviral vector downstream processing to improve infectious titer recoveries at each stage of unit operations. She also helped to expand the analytics development capabilities for assays used to define cell and gene therapy products.

Janet Rothberg

Development Manager, CCRM

Bio

Janet Rothberg is a Development Manager with the Center for Commercialization of Regenerative Medicine (CCRM) in Toronto and has been with the group since 2016. She received her PhD from the University of Ottawa in Cellular and Molecular Medicine. At CCRM, her work has focused on early scale-up of iPS-derived cell therapies. Her projects have included the translation of cardiac and hepatocyte differentiation protocols from 2D to suspension culture.